GoldenGolden
Biocytogen

Biocytogen

Biocytogen is a Wakefield, Massachusetts-based biotechnology company developing antibody drug discovery solutions based on gene editing and animal model studies.

Biocytogen engages in the development of antibody drug discovery solutions based on gene editing technologies and animal model research. The company was founded in 2009 and is headquartered in Wakefield, Massachusetts.

Timeline

September 2020
Biocytogen raises a $142,000,000 series D round from 3E Bioventures Capital, Baidu Capital, CMB International Capital Corporation, China Life Private Equity Investment Co, Cowin Capital, PICC Capital and SDIC Venture Capital.
August 2019
Biocytogen raises a $83,575,736 series D round from 3E Bioventures Capital, CMB International Capital Corporation, China Life Healthcare Fund and SDIC Venture Capital.
April 2018
Biocytogen raises a $63,105,068 series C round from 3E Bioventures Capital, CMB International Capital Corporation, Cowin Capital, Oriza Holdings and SDIC Venture Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Biocytogen Series D round September 2020
142,000,000
September 2020
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Biocytogen
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, ein Unternehmen, das sich der Beschleunigung der Entdeckung therapeutischer Antikörper widmet, hat den Erwerb eines dritten Beacon...
Biocytogen
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ --Biocytogen, une entreprise consacrée à l'accélération de la découverte d'anticorps thérapeutiques, a annoncé l'acquisition d'un troisième...
Biocytogen
February 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, una compañía dedicada a acelerar el descubrimiento de anticuerpos terapéuticos, ha anunciado la adquisición de un tercer sistema...
Biocytogen
February 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic...
Biocytogen
January 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the...
Biocytogen Boston Corp
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Beijing Biocytogen Co., Ltd. und Biocytogen Boston Corp. (zusammen als "Biocytogen" erfasst) gaben heute bekannt, dass sie mit Xencor, Inc....
Biocytogen Boston Corp
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Beijing Biocytogen Co., Ltd., Biocytogen Boston Corp (collectively as "Biocytogen") announced today that they have reached an agreement with...
Biocytogen Boston Corp
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Beijing Biocytogen Co., Ltd., Biocytogen Boston Corp (collectivement appelés « Biocytogen ») ont annoncé aujourd'hui qu'ils avaient conclu un...
Biocytogen Boston Corp
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Beijing Biocytogen Co., Ltd., Biocytogen Boston Corp (de forma colectiva, "Biocytogen"), anunció hoy que ha llegado a un acuerdo con Xencor,...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.